Results 71 to 80 of about 847 (163)

Novel insight into atogepant mechanisms of action in migraine prevention

Brain
Abstract Recently, we showed that while atogepant—a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist—does not fully prevent activation of meningeal nociceptors, it significantly reduces a cortical spreading depression (CSD)-induced early response probability in C fibres and late response probability in Aδ ...
Agustin Melo-Carrillo, Andrew M Strassman, Ron Broide, Aubrey Adams, Brett Dabruzzo, Mitchell Brin, Rami Burstein   +6 more
openaire   +2 more sources

Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis [PDF]

Background: Comparative evaluations of preventive migraine treatments can help inform clinical decision making for managing migraine in clinical practice.
Onishchenko, Kateryna, Ailani, Jessica, Halker Singh, Rashmi B., McAllister, Peter, Gandhi, Pranav, Dupont-Benjamin, Laure, Nahas, Stephanie J., Duan, Molly, Voller, Corey, Tassorelli, Cristina, Hemstock, Matthew   +10 more
core   +2 more sources

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults:a double-blind, randomised phase 2b/3 trial

, 2020
Background: Atogepant is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist under investigation for treatment of migraine.
Ailani, Jessica, Lu, Kaifeng, Trugman, Joel M., Szegedi, Armin, Goadsby, Peter J.; id_orcid, Finnegan, Michelle, Dodick, David W.   +6 more
core   +1 more source

Atogepant

American Journal of Health-System Pharmacy, 2021
openaire   +2 more sources

Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: Six-month real-world evidence [PDF]

Atogepant; Preventive treatment; Real worldAtogepant; Tratamiento preventivo; Mundo realAtogepant; Tractament preventiu; Món realBackground The discovery of calcitonin gene-related peptide (CGRP) as a key player in migraine pathophysiology has ...
RUSSO, Antonio, Aamodt, Anne Hege, Caronna, Edoardo, Sundal, Christina, Pozo-Rosich, Patricia, Seabi, Dineo, Silvestro, Marcello, Finkelstein, Ian, Tronvik, Erling, Ahlden, Adam   +9 more
core   +1 more source

GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures

The Journal of Headache and Pain
Background Atogepant, the first oral CGRP receptor antagonist approved for migraine prevention, has demonstrated efficacy and safety in randomized clinical trials (RCT). However, prospective real-world data are lacking.
Piero Barbanti, Gabriella Egeo, Francesca Pistoia, Cinzia Aurilia, Paola Scatena, Steno Rinalduzzi, Silvia Strumia, Antonio Salerno, Fabio Frediani, Andrea Galli, Massimo Autunno, Laura Di Clemente, Maurizio Zucco, Maria Albanese, Francesco Bono, Pietrantonio Bruno, Laura Borrello, Stefano Messina, Alberto Doretti, Angelo Ranieri, Cecilia Camarda, Rosario Vecchio, Valeria Drago, Giulia Fiorentini, Carlo Tomino, Stefano Bonassi, Paola Torelli, Alice Mannocci, for the Italian Migraine Registry (I-GRAINE) study group   +28 more
doaj   +1 more source

Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases

Frontiers in Pharmacology
BackgroundThis study aimed to investigate the real-world profile of adverse events (AEs) associated with gepant medications in the clinical treatment of migraines by analyzing data collected from the VigiAccess database and the U.S.
Qiaofang Liang, Xiaolin Liao, Hongwen Wu, Yushen Huang, Taolin Liang, Hailong Li, Hailong Li, Hailong Li   +7 more
doaj   +1 more source

Efficacy and safety of oral gepants for acute and preventive treatment of migraine: a systematic review of randomized placebo-controlled clinical trials

Headache Medicine
Introduction Migraine is a disabling neurological disorder affecting approximately 15% of the global population. Calcitonin gene-related peptide (CGRP) receptor antagonists (gepants) represent a novel oral therapeutic class developed specifically for ...
Laryssa Raphaely Vieira da Silva, Celiane Mendes da Silva, Maria Fernanda Silva dos Santos, Letícia Padilha Pereira Cavalcante, Luna Matos Capocci, Larissa Karla Santos de Santana Alves, Richelly Beatryz Alves de Vasconcelos, Clara Nolasco Pinto Monteiro, Herculano Ramirez Floro Alonso, Mário César de Lima Silva, Alden Rodrigues de Albuquerque, Letícia Januzi de Almeida Rocha   +11 more
doaj   +2 more sources

Oral Presentation

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source